We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock

Delisted

NKGN was delisted on the 4th of March, 2025.

25 hedge funds and large institutions have $65.3M invested in NKGen Biotech, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% less funds holding

Funds holding: 5525 (-30)

55% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 11

61% less capital invested

Capital invested by funds: $168M → $65.3M (-$103M)

91% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 33

Holders
25
Holders Change
-30
Holders Change %
-54.55%
% of All Funds
0.39%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
5
Reduced
11
Closed
33
Calls
Puts
Net Calls
Net Calls Change

NKGN Hedge Fund Activity: Q2 2023 in Review

25 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q2 2023, worth a combined $65.3M — down 61% from $168M a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of NKGN and 3 opened new positions — a net loss of 30 holders — while 11 trimmed existing stakes and 5 added.

The largest buyer was Fir Tree Capital Management, adding an estimated $2.58M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $13.7M sold.

  • 25 institutional investors held NKGen Biotech, Inc. Common Stock (NKGN) as of Q2 2023, down from 55 in Q1 2023.
  • Funds reported $65.3M of NKGen Biotech, Inc. Common Stock stock for Q2 2023, down 61% quarter-over-quarter.
  • 3 funds opened new NKGen Biotech, Inc. Common Stock positions in Q2 2023 and 33 closed out, a net change of -30 holders.
  • The largest NKGen Biotech, Inc. Common Stock buyer in Q2 2023 was Fir Tree Capital Management, an estimated $2.58M added.
  • The largest NKGen Biotech, Inc. Common Stock seller in Q2 2023 was Adage Capital Partners, an estimated $13.7M sold.

Based on aggregated 13F filings for Q2 2023.